Rodrigo Bolanos, MD
Cardiovascular Disease · Winter Haven, FLNPI 1962504456
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $62,425 of the $90,744 with a category attached, or 68.8%. 19 manufacturers reported payments, led by Medical Device Business Services, Inc. at 56.7% of the total. Reporting peaked in 2019 at $22,968 and has fallen 54.0% since, to $10,573 in 2025. Among cardiovascular disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 387 payments — averaging $234.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medical Device Business Services, Inc.$51K
- Johnson & Johnson$18K
- Biosense Webster, Inc.$16K
- Medtronic$3K
- Boston Scientific$1K
- Elutia, Inc.$145
- plus $628 from 13 others
Across 8 payments — averaging $941.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$8K
What the payments were for
- Consulting fees$62,42569%
- Speaking & faculty fees$16,81519%
- Travel & lodging$3,4764%
- Food & beverage$8,0289%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medical Device Business Services, Inc. | 60 | $51,492 |
| Johnson & Johnson | 27 | $18,101 |
| Biosense Webster, Inc. | 64 | $16,115 |
| Medtronic(3 entities) | 127 | $2,828 |
| Boston Scientific | 68 | $1,436 |
| Elutia, Inc. | 7 | $145 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $139 |
| Abbott | 6 | $118 |
| E.r. Squibb & Sons, L.L.C. | 4 | $67 |
| Biotronik Inc. | 2 | $57 |
| Coastal Medical Technologies LLC | 1 | $46 |
| Boehringer Ingelheim | 3 | $39 |
| Terumo Cardiovascular Systems Corporation | 2 | $35 |
| Cardiofocus, Inc. | 1 | $29 |
| Amgen | 2 | $29 |
| Penumbra, Inc. | 1 | $23 |
| Novartis | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Portola Pharmaceuticals, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Carto 3$54,392
- XARELTO$17,581
- Carto 3 System$10,635
- Carto Smarttouch$3,150
- Carto CFAE$3,150
- CartoSound$3,150
- WATCHMAN Access System$247
- Claria MRI$125
- Adapta$125
- Micra$113
- COBALT DR MRI SURESCAN$107
- Watchman$101
How this compares
$90,744 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 511 | $503,348 |
| XareltoRivaroxaban | 122 | $131,283 |
| Diltiazem 12hr ErDiltiazem Hcl | 94 | $16,238 |
| Dofetilide | 83 | $14,702 |
| CorlanorIvabradine Hcl | 12 | $9,868 |
| SotalolSotalol Hcl | 574 | $8,640 |
| Flecainide Acetate | 215 | $7,143 |
| Metoprolol Succinate | 621 | $6,632 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 18 | $5,405 |
| Amiodarone Hcl | 362 | $3,848 |
| Diltiazem Hcl | 100 | $2,008 |
| Mexiletine Hcl | 19 | $1,547 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 27 | $683 |
| Carvedilol | 67 | $513 |
| ClopidogrelClopidogrel Bisulfate | 19 | $241 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $18,101 | $131,283122 claims |
| AmgenCorlanor | $29 | $9,86812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Winter Haven
- Zaheed TaiWinter Haven$123K
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.